134 related articles for article (PubMed ID: 32285614)
21. Development of an electronic trigger tool at a children's hospital within an academic medical center.
Fortenberry M; Odinet J; Shah P; McKinzie C; Murphy K; Faircloth CB; Falato C; Pappas A
Am J Health Syst Pharm; 2019 Nov; 76(Supplement_4):S107-S113. PubMed ID: 31724037
[TBL] [Abstract][Full Text] [Related]
22. Establishment of a pediatric trigger tool based on Global Trigger Tool to identify adverse drug events of children: experience in a Chinese hospital.
Liu Y; Yan J; Xie Y; Bian Y
BMC Pediatr; 2020 Sep; 20(1):454. PubMed ID: 32993580
[TBL] [Abstract][Full Text] [Related]
23. Association of Surgical Treatment With Adverse Events and Mortality Among Medicare Beneficiaries With Proximal Humerus Fracture.
Floyd SB; Thigpen C; Kissenberth M; Brooks JM
JAMA Netw Open; 2020 Jan; 3(1):e1918663. PubMed ID: 31922556
[TBL] [Abstract][Full Text] [Related]
24. Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study.
Ram P; Tiu A; Lo KB; Parikh K; Shah M
Heart Fail Rev; 2019 Nov; 24(6):989-995. PubMed ID: 31175492
[TBL] [Abstract][Full Text] [Related]
25. Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology.
Hébert G; Netzer F; Kouakou SL; Lemare F; Minvielle E;
Int J Clin Pharm; 2018 Apr; 40(2):376-385. PubMed ID: 29446003
[TBL] [Abstract][Full Text] [Related]
26. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
27. The Emergency Department Trigger Tool: Validation and Testing to Optimize Yield.
Griffey RT; Schneider RM; Todorov AA
Acad Emerg Med; 2020 Dec; 27(12):1279-1290. PubMed ID: 32745284
[TBL] [Abstract][Full Text] [Related]
28. Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost.
Nazer LH; Eljaber R; Rimawi D; Hawari FI
J Oncol Pharm Pract; 2013 Dec; 19(4):298-304. PubMed ID: 23223402
[TBL] [Abstract][Full Text] [Related]
29. Validating the Chinese geriatric trigger tool and analyzing adverse drug event associated risk factors in elderly Chinese patients: A retrospective review.
Hu Q; Qin Z; Zhan M; Chen Z; Wu B; Xu T
PLoS One; 2020; 15(4):e0232095. PubMed ID: 32343726
[TBL] [Abstract][Full Text] [Related]
30. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.
Khrystolubova N; Shieh M; Patel AJ; Bailey R
J Oncol Pharm Pract; 2020 Jan; 26(1):13-22. PubMed ID: 30832554
[TBL] [Abstract][Full Text] [Related]
31. Proposal of a trigger tool to assess adverse events in dental care.
Corrêa CDTSO; Mendes W
Cad Saude Publica; 2017 Nov; 33(11):e00053217. PubMed ID: 29166475
[TBL] [Abstract][Full Text] [Related]
32. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
33. Association between insurance status and patient safety in the lumbar spine fusion population.
Tanenbaum JE; Alentado VJ; Miller JA; Lubelski D; Benzel EC; Mroz TE
Spine J; 2017 Mar; 17(3):338-345. PubMed ID: 27765713
[TBL] [Abstract][Full Text] [Related]
34. Global trigger tool in child psychiatry: Treatment safety evaluation in adolescents with an acute psychotic episode.
Ivashchenko D; Buromskaya N; Savchenko L; Shevchenko Y; Sychev D
Int J Risk Saf Med; 2020; 31(1):25-35. PubMed ID: 31594255
[TBL] [Abstract][Full Text] [Related]
35. Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital.
Carnevali L; Krug B; Amant F; Van Pee D; Gérard V; de Béthune X; Spinewine A
Ann Pharmacother; 2013 Nov; 47(11):1414-9. PubMed ID: 24285758
[TBL] [Abstract][Full Text] [Related]
36. Potentially inappropriate medication use in older patients with breast and colorectal cancer.
Karuturi MS; Holmes HM; Lei X; Johnson M; Barcenas CH; Cantor SB; Gallick GE; Bast RC; Giordano SH
Cancer; 2018 Jul; 124(14):3000-3007. PubMed ID: 29689595
[TBL] [Abstract][Full Text] [Related]
37. Using triggers in primary care patient records to flag increased adverse event risk and measure patient safety at clinic level.
Eggleton KS; Dovey SM
N Z Med J; 2014 Mar; 127(1390):45-52. PubMed ID: 24670589
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
[TBL] [Abstract][Full Text] [Related]
39. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
40. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability.
Lavan AH; O'Mahony D; Buckley M; O'Mahony D; Gallagher P
Oncologist; 2019 Sep; 24(9):e968-e977. PubMed ID: 30833488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
